Todd Davis on royalty revenue

About Todd Davis

Todd Davis, CEO of Ligand Pharmaceuticals, discussed the company's financial performance and strategy during the fourth quarter 2025 earnings call. He stated that core revenue grew from $108 million in 2022 to $240 million in 2025, with guidance of $265 million for 2026 and expectations of over $430 million by 2030. Davis noted that full-year royalty revenue grew 48% and adjusted EPS increased 42%. He described Ligand's royalty aggregation model, saying the company is "simply reinvesting our cash flows" and growing at 20% annually, with expected cash flow of $120 million over the next 12 months. Davis characterized the biotech financing market as "a little bit broken" and said the company is "pricing our deals the same way equity is priced because we're taking equity-like risk." He also commented on NIH funding cuts, describing them as "a blip in time" and expressing optimism that changes would direct more funding to innovation rather than university overhead. In separate appearances, Davis discussed his background as a former U.S. Navy pilot and surface warfare officer, describing the Navy as "probably the greatest training organization in the history of man." He also appeared in a 2024 interview as CEO of Endexx Corporation, a plant-based consumer products company, stating the company was growing 300% annually and had products in 10,000 U.S. retail stores. Additionally, Davis has been active as a religious speaker, delivering sermons and Bible classes in which he discussed Christian theology, including statements such as "there is no other way and there is no other hope and there is no other way to come through the Father except through Jesus."

Profile compiled from Todd Davis's verified public interviews and appearances. See all quotes & transcripts →